Monitoring Virological Responses to Interferon-Ribavirin and Interferon Monotherapy of Chronic Hepatitis C Re-treated due to Relapse or Non-response

References

• Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321: 1501–6.
   Google Scholar
• Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778–89.
   PubMed Web of Science ®Google Scholar
• Carithers RL Jr., Emerson SS. Therapy of hepatitis C: metaanalysis of interferon alfa-ab trials. Hepatology 1997; 26(3 Suppl 1): 83S–88S.
   Google Scholar
• Lai MY, Kao JH, Yang PM, et al. Long-term efficacy of ribavirin plus initerferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307–12.
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group [see comments]. N Engl J Med 1998; 339: 1485–92.
   Google Scholar
• Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426–32.
   Google Scholar
• Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351: 83–7.
   PubMed Web of Science ®Google Scholar
• Schalm SW, Weiland O, Hansen BE, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. Gastroenterology 1999; 117: 408–13.
   Google Scholar
• Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment or relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493–9.
   Google Scholar
• Barbaro G, Di Lorenzo G, Soldini M, et al. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study. Am J Gastroenterol 1998; 93: 2445–51.
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Shindo M, Fong TL, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992; 16: 649–54.
   PubMed Web of Science ®Google Scholar
• Camps J, Garcia N, Riezu-Boj JI, Civeira MP, Prieto J. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. J Hepatol 1993; 19: 408–12.
   Google Scholar
• Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25: 591–8.
   PubMed Web of Science ®Google Scholar
• Zoulim F, Haem J, Ahmed SS, et al. Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. J Viral Hepat 1998; 5: 193–8.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Schmidt JM, Lee JH, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998; 28: 245–52.
   Google Scholar
• Widell A, Shev S, Mansson S, et al. Genotyping of hepatitis C virus isolates by a modified polymerase chain reaction assay using type specific primers: epidemiological application. J Med Virol 1994; 44: 272–9.
   PubMed Web of Science ®Google Scholar
• Brillanti S, Miglioli M, Barbara L. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J Hepatol 1995; 23\(Suppl 2): 13–5; discussion 15–6.
   Google Scholar
• Schvarcz R, Yun ZB, Sonnerborg A, Weiland O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or nonsustained response to interferon alone. J Med Virol 1995; 46: 43–7.
   PubMed Web of Science ®Google Scholar
• Sostegni R, Ghisetti V, Pittaluga F, et al. Sequential versus concomitant administration of ribavirin and initerferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial. Hepatology 1998; 28: 341–6.
   PubMed Web of Science ®Google Scholar
• Andreone P, Gramenzi A, Cursaro C, et al. Interferon-alpha ribavirin in chronic hepatitis C resistant to previous interferonalpha course: results of a randomized multicenter trial. J Hepatol 1999; 30: 788–93.
   PubMed Web of Science ®Google Scholar
• Khakoo S, Glue P, Grellier L, et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998; 46: 563–70.
   PubMed Web of Science ®Google Scholar
• Tong MJ, Hwang SJ, Lefkowitz M, et al. Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin. J Gastroenterol Hepatol 1994; 9: 587–91.
   PubMed Web of Science ®Google Scholar
• Lee WM, Reddy KR, Tong MJ, et al. Early hepatitis C virus-RNA response predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group. Hepatology 1998; 28: 1411–5.
   Google Scholar
• Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998; 79: 2381–91.
   PubMed Web of Science ®Google Scholar
• Martin J, Navas S, Quiroga JA, Pardo M, Carreno V. Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients. Cytokine 1998; 10 : 635–44.
   Google Scholar
• Tam RC, Pai B, Bard J, et al. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol 1999; 30: 376–82.
   PubMed Web of Science ®Google Scholar
• Orito E, Mizokami M, Suzuki K, et al. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol 1995; 46: 109–15.
   PubMed Web of Science ®Google Scholar
• Izopet J, Payen JL, Alric L, et al. Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy. J Med Virol 1998; 54: 86–91.
   PubMed Web of Science ®Google Scholar
• McHutchison J, Blatt L, Sedghi-Vaziri A, Russell J, Schmid P, Conrad A. Is there an optimal time to measure quantitative HCV RNA to predict nonresponse following interferon treatment for chronic HCV infection? J Hepatol 1998; 29: 362–8.
   Google Scholar
• Zeuzem S, Lee JH, Franke A, et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27: 1149–56.
   PubMed Web of Science ®Google Scholar
• Lau JY, Mizokami M, Ohno T, Diamond DA, Kniffen J, Davis GL. Discrepancy between biochemical and virological responses to interferonalpha in chronic hepatitis C. Lancet 1993; 342: 1208–9.
   PubMed Web of Science ®Google Scholar
• Pockros PJ, Tong M, Lee WM, et al. Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study Group. J Viral Hepat 1998; 5: 271–6.
   PubMed Web of Science ®Google Scholar
• Brouwer JT, Hansen BE, Niesters HG, Schalm SW. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol 1999; 30: 192–8.
   PubMed Web of Science ®Google Scholar
• Tsubota A, Chayama K, Arase Y, et al. Factors useful in predicting the response to interferon therapy in chronic hepatitis C. J Gastroenterol Hepatol 1993; 8: 535–9.
   PubMed Web of Science ®Google Scholar
• Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050–6.
   PubMed Web of Science ®Google Scholar
• Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226–31.
   PubMed Web of Science ®Google Scholar